ALK and lung adenocarcinoma: Although the next generation ALK inhibitor alectinib (CH5424802) has shown efficacy in NSCLC (141), hypoxia was found to induce resistance to ALK inhibitors crizotinib and alectinib in lung adenocarcinoma by inducing an EMT phenotype (142).